strategy to treat low-intermediate risk prostate cancer (Pca). However, the tradi- tionally held view that most Pca are multi- focal remains a possible impediment to its application in the majority of cases. It has been suggested that in multifocal dis- ease focal therapy could target only the largest (index) lesion, because since sec- ondary tumors are small unlikely to con- tribute to disease outcome. The objec- tive of this study was to evaluate the role of PCa focally in selecting men for local therapy. Materials and Methods: There were 456 consecutive cases of whole mount radical prostatectomy samples evaluated (01/ 2008 to 12 / 2010). Pathology review evaluated number of tumor foci, overall Gleason score (GsS), Gleason score (GsF) and volume (TTV), extracapsular exten- sion (ECE) and seminal vesicle invasion (SVI). The index lesion was defined as the largest by volume. Patients suitable for focal ablation were defined as either having; a) unifocal , organ confined PCA, GsS 7 or; b) multifocal PCa (pT2, GsS 7) with one large index lesion and the remaining foci demonstrating fea- tures of clinically insignificant disease (TFV of all secondary foci 0,5 cc with GsF 6). Results: In total, 627 tumor foci were identified. Tumors were more often multi- focal, 489 (78%). There was no significant difference between unifocal and multifo- cal tumors with respect to total tumor volume (median 3.45 cc vs 2.24 cc; p=0.39), proportion of GsS 7 ( 30.7% vs31.8%; p=0.9) and proportion of locally advanced disease (31.8% vs 21.7%; p= 0.33). In multifocal disease, TTV, GsG, ECE and SVI of the tumor were almost invariably defined by the index lesion. Of the 402 secondary foci, 347 (86.1%) had volume 0.5 cc and 398 (99.0%) had Gleason 6. Using the defined criteria, 232 (50.9%) men in this series could be considered suitable for focal ablation of the index lesion. Conclusions: Although multiple cancer foci within the prostate gland is a com- mon feature in RP specimens, histological features of poor prognosis are arguably associated with the index lesion. Second- ary foci are typically small volume and well differentiated. Focal therapy may be suitable in a significant proportion of men currently undergoing radical surgery. Fur- ther prospective IRB approved trials are needed to evaluate the role of focal ther- apy which seeks to ablate only the index lesion. MP-13.11 Prediction of Prostate Cancer Tumour Volume from Biopsy Cores: A Simple Guide by Gland Volume Robinson S, Karim O, Laniado M, Motiwala H Wexham Park Hospital, Slough, UK Introduction and Objective: Better esti- mation of prostate cancer volume can be predicted from the number of cores positive on biopsy if the glands are strat- ified into small and large volumes.We routinely categorize patients into “high” or “low” volume disease according to the number of positive biopsies cores. The correlation between number of positive cores and tumour volume post prostatec- tomy is low. Allowing for the size of the gland on transrectal ultrasound better pre- dicts tumour volume if one takes into ac- count their volume. Materials and Methods: A prospective study of 210 radical prostatectomy pa- tients had their numbers of positive cores on biopsy plotted against the final patho- logical volume post surgery. Then the glands were divided into big and small and re plotted. For each graph a correla- tion coefficient was calculated. Results: For all patients. Conclusions: Many parameters are asso- ciated with final tumour volume. How- ever, in the clinical setting, usually PSA, Gleason score and number of cores posi- tive are used most commonly to dictate therapeutic options. The correlation de- creases with increasing gland size, yet often the same confidence is applied to large glands. Simply noting the gland volume allows one to better estimate confidently the final tumour volume in small glands (here taken to be 30cc or less). This is an arbitrary cut off, but like PSA density, allows a quick simple assessment of biological aggression. MP-13.12 Robotic Assisted Laparoscopic Prostatectomy (RALP): Perioperative Complications and Oncological Outcomes MP-13.11, Figure 1. MP-13.11, Figure 2. MODERATED POSTER SESSIONS S128 UROLOGY 78 (Supplement 3A), September 2011